ロード中...
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
AIM: Maintenance treatment in ulcerative colitis should be as convenient as possible, to increase the chance of compliance. MMX mesalazine is a once-daily, high-strength (1.2 g/tablet) formulation of 5-aminosalicylic acid. This study evaluated the safety and efficacy of MMX mesalazine dosed once or...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2008
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2564831/ https://ncbi.nlm.nih.gov/pubmed/18272546 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2007.138248 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|